Register Login

Perspective Therapeutics Inc (CATX)

(56% Neutral) Perspective Therapeutics, Inc. (CATX) Announces Enrollment Update for treatments Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 12:27 p.m.

    📋 Perspective Therapeutics, Inc. (CATX) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 07:25:31

    Event Type: Clinical Trial Update

    Event Details:

    Perspective Therapeutics Inc (CATX) Announces Clinical Trial Update Perspective Therapeutics Inc (CATX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: treatments, patients
    • Diseases/Conditions: Cohort 2 regardless of SSTR2 expression profile
    • Clinical Stage: clinical trial, Clinical Trial
    • Collaboration: CATX
      • targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company's website at www.perspectivetherapeutics.com. Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (Perspective Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    [212Pb]VMT-α-NET DRUG Phase PHASE1 Neuroendocrine Tumors Unresectable ClinicalTrials.gov
    [203Pb]VMT-α-NET DRUG Phase PHASE1 Neuroendocrine Tumors Unresectable ClinicalTrials.gov
    [212Pb] VMT-α-NET DRUG Phase EARLY_PHASE1 Neuroendocrine Tumors ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE1 Recurrent Melanoma (Skin) ClinicalTrials.gov
    [212Pb]VMT01 DRUG Phase PHASE1 Recurrent Melanoma (Skin) ClinicalTrials.gov
    [203Pb]VMT01 DRUG Phase PHASE1 Recurrent Melanoma (Skin) ClinicalTrials.gov
    [212Pb]Pb-PSV359 DRUG Phase PHASE1 Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    [203Pb]Pb-PSV359 DRUG Phase PHASE1 Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Perspective Therapeutics Inc
    • CIK: 0000728387
    • Ticker Symbol: CATX
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories